Have a feature idea you'd love to see implemented?
Let us know!
EXAS Exact Sciences Corp
Price (delayed)
$68.36
Market cap
$12.63B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$14.86B
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first
Highlights
Exact Sciences's EPS has soared by 60% YoY and by 27% from the previous quarter
The company's net income has surged by 59% YoY and by 27% QoQ
The company's quick ratio rose by 39% QoQ but it fell by 7% YoY
The company's debt rose by 8% QoQ and by 8% YoY
Key stats
What are the main financial stats of EXAS
Market
Valuations
Earnings
Shares outstanding
184.77M
Market cap
$12.63B
Enterprise value
$14.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.95
Price to sales (P/S)
4.82
EV/EBIT
N/A
EV/EBITDA
159.83
EV/Sales
5.69
Revenue
$2.61B
EBIT
-$148.53M
EBITDA
$92.99M
Free cash flow
-$14.96M
Per share
Balance sheet
Liquidity
EPS
-$0.96
Free cash flow per share
-$0.08
Book value per share
$17.3
Revenue per share
$14.17
TBVPS
$13.36
Total assets
$6.67B
Total liabilities
$3.48B
Debt
$2.76B
Equity
$3.19B
Working capital
$783.85M
Debt to equity
0.87
Current ratio
2.17
Quick ratio
1.81
Net debt/EBITDA
24
Margins
Efficiency
Dividend
EBITDA margin
3.6%
Gross margin
73.2%
Net margin
-6.7%
Operating margin
-7.4%
Return on assets
-2.7%
Return on equity
-5.6%
Return on invested capital
-4%
Return on capital employed
-2.5%
Return on sales
-5.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXAS stock price
How has the Exact Sciences stock price performed over time
Intraday
2.94%
1 week
3.64%
1 month
19.66%
1 year
5.09%
YTD
-7.6%
QTD
0.35%
Financial performance
How have Exact Sciences's revenue and profit performed over time
Revenue
$2.61B
Gross profit
$1.91B
Operating income
-$193.94M
Net income
-$175.01M
Gross margin
73.2%
Net margin
-6.7%
The company's net margin has surged by 64% YoY and by 29% QoQ
The company's net income has surged by 59% YoY and by 27% QoQ
The operating margin has surged by 59% year-on-year and by 24% since the previous quarter
The operating income has surged by 53% year-on-year and by 21% since the previous quarter
Growth
What is Exact Sciences's growth rate over time
Valuation
What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.95
P/S
4.82
EV/EBIT
N/A
EV/EBITDA
159.83
EV/Sales
5.69
Exact Sciences's EPS has soared by 60% YoY and by 27% from the previous quarter
The stock's price to book (P/B) is 12% less than its 5-year quarterly average of 4.5 but 7% more than its last 4 quarters average of 3.7
The company's equity rose by 4.4% YoY
EXAS's price to sales (P/S) is 39% less than its 5-year quarterly average of 7.9 but 4.8% more than its last 4 quarters average of 4.6
EXAS's revenue is up by 14% year-on-year and by 3% since the previous quarter
Efficiency
How efficient is Exact Sciences business performance
Exact Sciences's ROS has soared by 69% YoY and by 30% from the previous quarter
The company's return on invested capital has surged by 65% YoY and by 30% QoQ
EXAS's return on assets has surged by 61% year-on-year and by 29% since the previous quarter
The ROE has soared by 60% YoY and by 27% from the previous quarter
Dividends
What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXAS.
Financial health
How did Exact Sciences financials performed over time
The total assets is 92% more than the total liabilities
The company's quick ratio rose by 39% QoQ but it fell by 7% YoY
EXAS's current ratio is up by 32% QoQ but it is down by 10% YoY
The company's debt is 13% lower than its equity
The company's debt rose by 8% QoQ and by 8% YoY
EXAS's debt to equity is up by 6% since the previous quarter and by 3.6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.